EGFR variant III (vIII) is expressed in about 30% of newly diagnosed GBM, and represents, in patients surviving a year or longer, a negative prognostic indicator, regardless of other factors such as extent of resection and age [84,122]. The gene discussed is EGFR; the disease is glioblastoma.